AUSTIN, Texas & CAMBRIDGE, Mass.— (April 1, 2019) — Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K […]
Thermo Fisher recently announced it is buying Brammer Bio, which provides viral vector manufacturing services for gene and cell therapy companies. This acquisition is one of the many we have seen recently, as several other large pharmaceutical companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, including Roche’s acquisition […]
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019. The one-day […]
Last month, Genprex’s President and Chief Operating Officer, Julien Pham, attended the IASLC 2019 Targeted Therapies of Lung Cancer Meeting in Santa Monica, California. This meeting brought together a variety of key players working on the newest therapies for lung cancer including researchers, oncologists, physicians, patient advocacy groups and even clinical-stage companies, such as Genprex. […]
Roche’s acquisition of Spark Therapeutics confirms that gene therapy has finally made its debut as a treatment option for serious diseases Chemotherapy, radiation, and more recently, immunotherapy have been the primary treatments for patients with cancer, and there has been little progress in terms of “huge medical breakthroughs” for cancer treatment for many years. While industry and […]
Genprex announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of John N. Bonfiglio, PhD, to the company’s Board of Directors. In recent years, Dr. Bonfiglio served as President and CEO of Oragenics, Inc. and most recently as […]
Noble Capital Markets’ Fifteenth Annual Investor / Equity Conference AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 23, 2019– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that its President and Chief Operating Officer, Julien Pham, MD, MPH, will deliver a presentation about the company’s unique, leading-edge […]
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 3, 2019– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare finance at the Hilton San Francisco Union […]
Company Placing Priority on Investor Engagement with New Website, Email Updates AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of […]